Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HHS Secretary Nominee Azar Advances In Senate

Executive Summary

US HHS Secretary Nominee Alex Azar was approved by the Senate Finance Committee on Jan. 17, sending his nomination to the full Senate for consideration. The former pharmaceutical company executive supports approval of additional telehealth reimbursements and, at a recent confirmation hearing, he discussed more access to durable medical equipment for patients in competitive bidding program areas.

You may also be interested in...



FDA, CMS Will Use Parallel Review For Pain-Control Alternatives To Opioids, Medicare Official Says

The Medicare agency is working with US FDA on a parallel review process for non-addictive medical device pain control products and non-opioid drug alternatives to treat chronic pain, Kimberly Brandt, a CMS deputy administrator, told the Senate Finance Committee April 19.

Dems Come Out Swinging During Azar Senate HELP Committee Hearing

During his first Senate confirmation hearing, top Democrats attacked Trump HHS secretary nominee Alex Azar for his ties to the pharmaceutical industry and support of right-wing ideology espoused by the White House.

Telehealth Reforms Praised At Senate Hearing

Insurers and a neurologist testifying at a May 16 Senate Finance Committee hearing on the CHRONIC Care Act praised the bill's telehealth provisions. Committee Chairman Orrin Hatch, R-Utah, says he plans to mark up the bill, which has been under development for two years, this week.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122037

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel